Company intelligence / Profile preview

Boston Biomedical

Cambridge, Massachusetts, USA

Ownership: Private
Employees: ~150
Development stage: Other

Overview

Boston Biomedical is a biotechnology company specializing in the discovery and development of first-in-class cancer therapeutics that target cancer stem cell (CSC) pathways. Founded in 2006, the company developed a proprietary platform focused on "cancer stemness," aiming to inhibit the signaling pathways that allow cancer cells to self-renew and resist conventional treatments. Their lead candidate, napabucasin, was a pioneering small molecule designed to target STAT3-mediated gene transcription. The company was acquired by Sumitomo Dainippon Pharma in 2012 to anchor its global oncology pipeline. In 2020, it was merged with other subsidiaries to form Sumitomo Pharma Oncology.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Sumitomo Dainippon Pharma

Beyond the preview

Go deeper on Boston Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Boston Biomedical.

Explore the full profile